16Jul, 2024 CereVasc Announces Appointments of New DirectorsAdmin2024-07-18T18:46:24+00:00July 16th, 2024|Press Release|Read More
13May, 2024 CereVasc Announces $70 Million Series B Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusAdmin2024-05-28T21:41:18+00:00May 13th, 2024|Press Release|Read More
07May, 2024 CereVasc Receives FDA IDE Approval for the STRIDE Pivotal Study of the eShunt System for Treatment of Normal Pressure Hydrocephaluscerevasc2024-05-28T21:43:24+00:00May 7th, 2024|Press Release|Read More
07Feb, 2024 CereVasc’s eShunt® System to be Presented at the International Stroke Conference by Dr. Pedro Lylykcerevasc2024-05-10T14:17:27+00:00February 7th, 2024|Press Release|Read More
23Jan, 2024 CereVasc’s eShunt® System Study Data Presented at the ABC WIN Seminarcerevasc2024-05-10T14:32:14+00:00January 23rd, 2024|Press Release|Read More
03Oct, 2023 CereVasc Announces 30th Patient Treated in Pilot Studies of the eShunt® System to treat Communicating HydrocephalusAdmin2023-12-20T22:01:46+00:00October 3rd, 2023|Press Release|Read More
